Skip to main content

Table 1 Patient demographic data and clinical characteristics of responding group and nonresponding group

From: Comparison of the pre-treatment functional MRI metrics’ efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy

  RG(n = 36) NRG(n = 20) t/χ2 p
Age 43.75 ± 13.14 48.75 ± 11.92 1.41 0.165
Gender    0.003 0.959
 Male 29 (80.6%) 17 (85.0%)   
 Female 7 (19.4%) 3 (15.0%)   
AJCC T stage    2.716 0.444
 T1 2 (5.6%) 0 (0%)   
 T2 18 (50.0%) 7 (35.0%)   
 T3 10 (27.8%) 7 (35.0%)   
 T4 6 (16.7%) 6 (30.0%)   
A CC N stage    2.869 0.406
 N0 1 (2.8%) 1 (5.0%)   
 N1 5 (13.9%) 6 (30.0%)   
 N2 16 (44.4%) 6 (30.0%)   
 N3 14 (38.9%) 7 (35.0%)   
Pathological classification    3.283 0.224
 non-cornification undifferentiated 19 (52.8%) 7 (35.0%)   
 low differentiated 15 (41.7%) 9 (45.0%)   
 moderately differentiated 2 (5.6%) 4 (20.0%)   
IC regimes    1.344 0.246
 Docetaxel + Cisplatin 27 (75%) 12 (60%)   
 Paclitaxel-albumin + Cisplatin 9 (25%) 8 (40%)   
  1. Note: data represents the number of patients and data in parentheses are percentages. Abbreviations: IC = induction chemotherapy. Abbreviations: RG: responding group; NRG: nonresponding group; IC: induction chemotherapy